Literature DB >> 33057875

LncRNA XIST Promotes Migration and Invasion of Papillary Thyroid Cancer Cell by Modulating MiR-101-3p/CLDN1 Axis.

Yong-Liang Du1, Yan Liang1, Yan Cao1, Le Liu1, Jian Li2, Guang-Qing Shi3.   

Abstract

Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy in the worlds. Long non-coding RNA X-inactive specific transcript (XIST) was found to upregulate in PTC tissues and cell lines. However, the molecular mechanism underlying PTC metastasis and whether XIST plays regulatory role in PTC are still largely unknown. qRT-PCR was performed to detect the expression of lncRNA XIST and mRNAs. Western blotting was carried out to detect CLDN1, MMP2, and MMP9. Transwell assay was used to detect migration and invasion. Starbase bioinformatics prediction and luciferase assay were used to validate the relationship of miR-101-3p and XIST or CLDN1. LncRNA XIST was upregulated in PTC tissues and cells. XIST knockdown suppressed migration and invasion of PTC cells. XIST could directly bind with miR-101-3p. Overexpression of miR-101-3p suppressed migration and invasion of PTC cells. CLDN1 was the target of miR-101-3p, and overexpression of CLDN1 can reverse the inhibition of cell migration and invasion by miR-101-3p, What's more, miR-101-3p inhibition and CLDN1 overexpression can reverse the affection of sh-XIST on migration and invasion of PTC cells inhibition. XIST promotes migration and invasion of papillary thyroid cancer cell via directly regulating miR-101-3p/CLDN1 axis, which is a novel mechanistic of XIST in the regulation of PTC.

Entities:  

Keywords:  CLDN1; PTC; lncRNA XIST; miR-101-3p

Mesh:

Substances:

Year:  2020        PMID: 33057875     DOI: 10.1007/s10528-020-09985-8

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  5 in total

1.  Blood-Brain Barrier Permeability Is Exacerbated in Experimental Model of Hepatic Encephalopathy via MMP-9 Activation and Downregulation of Tight Junction Proteins.

Authors:  Saurabh Dhanda; Rajat Sandhir
Journal:  Mol Neurobiol       Date:  2017-05-18       Impact factor: 5.590

Review 2.  Diagnosis and treatment of patients with thyroid cancer.

Authors:  Quang T Nguyen; Eun Joo Lee; Melinda Gingman Huang; Young In Park; Aashish Khullar; Raymond A Plodkowski
Journal:  Am Health Drug Benefits       Date:  2015-02

3.  MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinoma.

Authors:  Huadong Zhao; Haili Tang; Qike Huang; Bo Qiu; Xiaomin Liu; Dong Fan; Li Gong; Hang Guo; Chong Chen; Shixiong Lei; Lu Yang; Jianguo Lu; Guoqiang Bao
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

4.  LncRNA NORAD promotes thyroid carcinoma progression through targeting miR-202-5p.

Authors:  Hongjiang He; Hao Yang; Daming Liu; Rong Pei
Journal:  Am J Transl Res       Date:  2019-01-15       Impact factor: 4.060

Review 5.  Recurrence of papillary thyroid cancer after optimized surgery.

Authors:  Clive S Grant
Journal:  Gland Surg       Date:  2015-02
  5 in total
  11 in total

Review 1.  Emerging role of competing endogenous RNA and associated noncoding RNAs in thyroid cancer.

Authors:  Qian Bai; Zhenjie Pan; Ghulam Nabi; Farooq Rashid; Yang Liu; Suliman Khan
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

2.  NEAT1 can be a diagnostic biomarker in the breast cancer and gastric cancer patients by targeting XIST, hsa-miR-612, and MTRNR2L8: integrated RNA targetome interaction and experimental expression analysis.

Authors:  Mansoureh Azadeh; Ali Salehzadeh; Kamran Ghaedi; Soheila Talesh Sasani
Journal:  Genes Environ       Date:  2022-05-17

Review 3.  Long non-coding RNA XIST: a novel oncogene in multiple cancers.

Authors:  Jun Yang; Manlong Qi; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Mol Med       Date:  2021-12-20       Impact factor: 6.354

4.  LINC01087 Promotes the Proliferation, Migration, and Invasion of Thyroid Cancer Cells by Upregulating PPM1E.

Authors:  Ying Yin; Jianhao Huang; Hongyan Shi; Yijie Huang; Ziyang Huang; Muye Song; Liping Yin
Journal:  J Oncol       Date:  2022-03-25       Impact factor: 4.375

5.  Long non-coding RNA CATIP antisense RNA 1 (lncRNA CATIP-AS1) downregulation contributes to the progression and metastasis of thyroid cancer via epithelial-mesenchymal transition (EMT) pathway.

Authors:  Fujian Qi; Ji'Ao Tang; Zhenling Cai; Gang Wang; Zhijun Wang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

6.  XIST sponges miR-320d to promote chordoma progression by regulating ARF6.

Authors:  Yonggang Wang; Zhouzhou Tang; Weichun Guo
Journal:  J Bone Oncol       Date:  2022-07-16       Impact factor: 4.491

Review 7.  Noncoding RNAs in Thyroid-Follicular-Cell-Derived Carcinomas.

Authors:  Marco De Martino; Francesco Esposito; Maria Capone; Pierlorenzo Pallante; Alfredo Fusco
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

8.  Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review).

Authors:  Rui-Jie Ma; Chao Ma; Kang Hu; Meng-Meng Zhao; Nan Zhang; Zhi-Gang Sun
Journal:  Int J Oncol       Date:  2022-07-20       Impact factor: 5.884

Review 9.  X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis.

Authors:  Soudeh Ghafouri-Fard; Sepideh Dashti; Molood Farsi; Mohammad Taheri; Seyed Ali Mousavinejad
Journal:  Front Cell Dev Biol       Date:  2021-06-11

Review 10.  The lncRNAs at X Chromosome Inactivation Center: Not Just a Matter of Sex Dosage Compensation.

Authors:  Chiara Siniscalchi; Armando Di Palo; Aniello Russo; Nicoletta Potenza
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.